1984 – 1988 Davidson College, Cum Laude, B.S., Pre-Medicine Major
1988 – 1992 UNC at Chapel Hill School of Medicine, M.D.
1992 – 1993 Internal Medicine Intern, UNC Memorial Hospitals
1993 – 1995 Internal Medicine Resident, UNC Memorial Hospitals
1995 – 1996 Chief Resident of Internal Medicine, UNC Memorial Hospitals
1996 – 1999 Oncology Fellowship, University of Washington
The overall goals of Dr. Stirewalt’s research are to identify novel biomarkers for hematopoietic malignancies and to understand how these biomarkers may function to promote the development of diseases. Dr. Stirewalt’s lab, in collaboration with other labs at the FHCRC and across the country, uses novel high throughput technologies to achieve these goals. These technologies include next generation sequencing of DNA, mRNA, and miRNA, as well as evaluation of proteomic signatures. These novel biomarkers are then validated in larger cohorts of patients, using samples from cooperative groups such as the Southwest Oncology Group (SWOG) and Children’s Oncology Group (COG). Given the strong link between aging and myeloid malignancies, Dr Stirewalt is also investigating how selective candidates may link aging to myeloid transformation. Such studies may identify early transforming events that can be used as early predictors for the development of these diseases or to develop novel therapeutic agents that reverse prior to the development of the disease.
Dr. Stirewalt’s clinical expertise lies within the evaluation and treatment of patients with hematopoietic malignancies, with a particular interest in those patients with leukemia. He has been an active member of the FHCRC’s transplant program for over 10 years and routinely oversees the care of patients receiving either an autologous or allogeneic transplant at the Center. In addition, he remains an active member of multiple onl local and national committees, which develop standards for the care of patients with hematopoietic malignancies. He currently is the Director for the FRCRC/UW Leukemia Repository and serves as an member of the National Comprehensive Cancer Network (NCCN) Guideline Committee for Senior Adult Oncology.
2012 – 2017 NIH R01. CA 160872-01A1 (P.I. Stirewalt, D.L.): “Discovery and Optimization of AML Prognostic Biomarkers.”